Goldman Sachs
PRNB

Goldman Sachs’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Goldman Sachs’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,000
Closed -$891K – 5618
2020
Q1 		$891K Buy
+15,000
New +$874K ﹤0.01% 3838

Other funds holding PRNB

Ohio Public Employees Retirement System (OPERS)
Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $30.9B AUM 29.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Public Employees Retirement Association of Colorado
Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ADL
Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return

Goldman Sachs's PRNB Position: Q3 2020 in Review

Goldman Sachs sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 373,720 shares — an estimated $22.3M sold.

Goldman Sachs first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $22.3M in Q2 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • Goldman Sachs reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Goldman Sachs sold 373,720 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $22.3M.
  • Goldman Sachs first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • Goldman Sachs's Principia Biopharma Inc. Common Stock position peaked at $22.3M in Q2 2020.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.